|

PF-08046054 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: SGN-PDL1V

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Seagen, a wholly owned subsidiary of Pfizer1
  • Pfizer1

Indications

  • Lung Cancer2
  • Cancer2
  • Liver Disease1
  • Non-Small Cell Lung Carcinoma1
  • Non-small Cell Carcinoma1

Alabaster, Alabama1 trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Alabama Oncology

Phase 3

Birmingham, Alabama1 trial

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.